# Canadian Pegvisomant Compassionate Study In Acromegalic Patients

> **NCT00151437** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 30 (—)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Pegvisomant treatment
- **PROCEDURE:** Medical History, demographics
- **PROCEDURE:** Sign and symptoms: questionnaire
- **PROCEDURE:** Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT
- **PROCEDURE:** MRI

## Key facts

- **NCT ID:** NCT00151437
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 30 (—)
- **Last updated:** 2008-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151437, "Canadian Pegvisomant Compassionate Study In Acromegalic Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00151437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*